Compare Citius Pharmaceuticals Inc (CTXR) vs Financial Select Sector SPDR Fund (XLF) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Financial Select Sector SPDR Fund — how do they compare? Citius Pharmaceuticals Inc trades at $0.53 (market cap $14.64M), while Financial Select Sector SPDR Fund trades at $56.32. The key difference: Financial Select Sector SPDR Fund is trading nearer its 52-week high, Citius Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| CTXR | XLF | |
|---|---|---|
Market Cap | $14.64M | — |
Sector | Health | — |
52-Week High | $1.82 | $56.41 |
52-Week Low | $0.53 | $47.80 |
Enterprise Value | $10.86M | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.54, down 7.33% in the last session, with a bearish technical signal from moving averages. The company reported a net loss of $37.43M for 2025 and has missed earnings expectations for the last three quarters. Recent news highlights progress with LYMPHIR, including Phase 1 data presentations at ASCO and international expansion, alongside $5.6M in net revenue for the first half of 2026.
Despite a high analyst buy consensus (83%), CTXR faces significant fundamental challenges with negative profitability and cash burn. Investment opportunity hinges on successful commercialization of LYMPHIR, but risks include ongoing losses, dilution from recent financing, and clinical execution uncertainties. The stock remains speculative with high risk-reward dynamics.
XLF trades at $56.07, up 0.65% with a bullish technical outlook supported by moving averages. The ETF benefits from strong bank earnings expectations and potential Federal Reserve rate hikes. Recent news highlights sector resilience amid geopolitical tensions and AI-driven market shifts.
Outlook remains positive with earnings season as a catalyst, though risks include economic slowdowns and regulatory pressures. Analyst sentiment leans bullish with institutional focus on dividend growth and financial stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Financial Select Sector SPDR Fund
The fund generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes securities of companies from the following industries: diversified financial services; insurance; banks; capital markets; mortgage real estate investment trusts; consumer finance; thrifts; and mortgage finance. The fund is non-diversified.
Read more on XLF →
